REMARKS

The Office Action mailed April 5, 2002, has been received and its contents carefully noted. The application was deemed to have failed to comply with the Sequence Listing Requirements.

Applicants respectfully submit that the specification and claims as amended herein conform to the Sequence Listing Requirements. Support may be found in the specification generally. No statutory new matter has been added. Reconsideration is respectfully requested.

Applicants note that some sequences are sometimes listed in an unconventional order, C-terminal to N-terminal order.

Submission of Substitute Sequence Listing

In connection with the Substitute Sequence Listing submitted herewith, the undersigned hereby states that:

1. In accordance with 37 C.F.R. 1.825(a), the Substitute Sequence Listing does not contain new matter.
2. In accordance with 37 C.F.R. 1.825(b), the content on the attached paper copy and the attached computer readable copy of the Substitute Sequence Listing are the same.
3. All the statements made herein are true and that

all statements made on information and belief are believed to be true, and that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Applicants also enclose herewith two floppy disks containing the computer readable form of the Substitute Sequence Listing and a copy of the Notice to File Corrected Application Papers.

Petition for Extension of Time

A Petition for an Extension of Time for Two (2) months under 37 CFR §1.136 and the appropriate fee under 37 CFR § 1.17 are filed herewith to extend the due date for responding to the Official action to July 5, 2002.

CONCLUSION

Accordingly, in view of the foregoing amendments, the Examiner is respectfully requested to reconsider and withdraw the rejection of the claims and to find this application to be in allowable condition.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned **"Version With Markings To Show Changes Made To Claims"**, **"Substitute Pages Of The Specification"** and **"Version With Markings To Show Changes Made To Specification"**.

If the Examiner believes that a conference would be of value in expediting the prosecution of this application, the Examiner is invited to telephone the undersigned to arrange for such a conference.

Respectfully submitted,
JACOBSON HOLMAN PLLC

By 
Harvey B. Jacobson, Jr.
Reg. No. 20,851

400 Seventh Street, N.W.
Washington, D.C. 20004-2201
(202) 638-6666
Date: July 5, 2002
Atty. Docket: 162/P63882US0

Version With Markings To Show Changes Made To Claims

57. (Amended) The method according to claim 56, wherein the LPA obtained [provide] provides a C-terminal presentation of the C-terminal sequence Pro-Lys-Lys-Pro (Seq. ID 7) of OspC.

62. (Amended) The method according to claim 60, wherein at least one of the peptide sequences comprises the ESAT-6, 51-70 sequence or the ESAT-6, 1-17 sequence protein HO-GlnLeuAlaAsnAsnLeu-GluThrAlaThrAlaAspTrpLysGlnGlnValGlyGlnTyr-H (HO-Seq. ID 2-H) of *Mycobacterium tuberculosis* HO-AlaSerAlaAlaAlaGluIleGlyAlaPheAsn-TrpGlnGlnGluThrMet-H (HO-Seq. ID 3-H).

63. (Amended) The method according to claim 46, wherein the LPA obtained is selected from the group consisting of

[LPA-I]: $FmocN(CH_2CO\text{-}ProValValAlaGluSerProLysLysPro\text{-}OH)_2$ ($FmocN(CH_2CO\text{-}$Seq. ID 1-$OH)_2$),

[LPA-II]: $biotin\text{-}NH(CH_2)_5CON(CH_2CO\text{-}ProValValAlaGluSerProLysLysPro\text{-}OH)_2$ ($biotin\text{-}NH(CH_2)_5CON(CH_2CO\text{-}$Seq. ID 1-$OH)_2$),

[LPA-III]: $NH_2CH(CH_2CO\text{-}ProValValAlaGluSerProLysLysPro\text{-}OH)_2$ ($NH_2CH(CH_2CO\text{-}$Seq. ID 1-$OH)_2$),

[LPA-IV]: H-Lys-NHCH(CH_2CO-ProValValAlaGluSerProLysLysPro-OH)$_2$ (H-Lys-NHCH(CH_2CO-Seq. ID 1-OH)$_2$),

[LPA-VII]: CH_2(CH_2CO-β-Ala-β-AlaLysGluProAsnLysGlyValAsnPro-AspGluValβAla-OH)$_2$ (CH_2(CH_2CO-β-Ala-β-Ala-Seq. ID 4-βAla-OH)$_2$),

[LPA-VIII]: HC(CH_2CO-LysGluProAsnLysGlyValAsnProAspGluVal-βAla)$_2$COOH (HC(CH_2CO-Seq. ID 4-βAla)$_2$COOH),

[LPA-IX]: Fmoc-NHCH(CH_2CO-AspArgValTyrIleHisProPheHisLeu-NH_2)$_2$ (Fmoc-NHCH(CH_2CO-Seq. ID 5-NH_2)$_2$),

[LPA-X]: Aloc-NHCH(CH_2CO-AspArgValTyrIleHisProPheHisLeu-NH_2)$_2$ (Aloc-NHCH(CH_2CO-Seq. ID 5-NH_2)$_2$) and

[LPA-XI]: Fmoc-AspProThrGlnAsnIleProProGly-NHCH(CH_2CO-AspArg-ValTyrIleHisProPheHisLeu-NH_2)$_2$ (Fmoc-Seq. ID 6-NHCH(CH_2CO-Seq. ID 5-NH_2)$_2$).

65. (Amended) The method according to claim 60, wherein the LPA obtained is selected from the group consisting of

[LPA-V]: (HO-ProLysLysProSerGluAlaValValPro-$COCH_2$)$_2$CH-NH-Lys-(GlnLeuAlaAsnAsnLeuGluThrAlaThrAlaAspTrpLysGlnGlnValGlyGlnTyr-H)$_2$ ((HO-Seq. ID 12-$COCH_2$)$_2$CH-NH-Lys-(Seq. ID 2-H)$_2$), and

[LPA-VI]: (HO-ProLysLysProSerGluAlaValValPro-$COCH_2$)$_2$N-Lys(AlaSer-AlaAlaAlaGluIleGlyAlaPheAsnTrpGlnGlnGluThrMet-H)$_2$ ((HO-Seq. ID 12-$COCH_2$)$_2$N-Lys(Seq. ID 3-H)$_2$).